1995•PubMedRequires access

Pharmacoeconomics: an emerging discipline.

C Letizia

Open publisher page 5 citations

Abstract

The economic pressures of cost containment, pricing competition, and managed care have bootstrapped the application of health economic evaluation into the specialized area of pharmacoeconomics. The rapid development of the field has lead to criticism within the discipline and skepticism from consumers of pharmacoeconomic studies. The need for consensus upon standards of design and analysis will result in guidelines and more stringent peer review. The relative merits of current approaches are reviewed with respect to the limitations and generalizability of each type of study and common pitfalls in the design, analysis, and promotion of pharmacoeconomic studies. Future trends and regulatory issues are discussed. Finally, the role of pharmacoeconomics in drug development and marketing is evaluated.

About this research paper

What this paper is about

The economic pressures of cost containment, pricing competition, and managed care have bootstrapped the application of health economic evaluation into the specialized area of pharmacoeconomics. The rapid development of the field has lead to criticism within the discipline and skepticism from consumers of pharmacoeconomic studies. The need for consensus upon standards of design and analysis will result in guidelines and more stringent peer review. The relative merits of current approaches are reviewed with respect to the limitations and generalizability of each type of study and common pitfalls in the design, analysis, and promotion of pharmacoeconomic studies. Future trends and regulatory issues are discussed. Finally, the role of pharmacoeconomics in drug development and marketing is evaluated.

Why it matters

OpenAlex reports 5 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

The economic pressures of cost containment, pricing competition, and managed care have bootstrapped the application of health economic evaluation into the specialized area of pharmacoeconomics. The rapid development of the field has lead to criticism within the discipline and skepticism from consumers of pharmacoeconomic studies. The need for consensus upon standards of design and analysis will result in guidelines and more stringent peer review. The relative merits of current approaches are reviewed with respect to the limitations and generalizability of each type of study and common pitfalls in the design, analysis, and promotion of pharmacoeconomic studies. Future trends and regulatory issues are discussed. Finally, the role of pharmacoeconomics in drug development and marketing is evaluated.

Key concepts: Pharmacoeconomics, Generalizability theory, Criticism, Skepticism, Promotion (chess), Management science, Risk analysis (engineering), Health economics

Related papers

Back to paper searchBrowse research topicsOriginal source
Pharmacoeconomics: an emerging discipline. — Research Paper | ScholarLens